Talazoparib works by inhibiting the enzyme PARP, which is essential for repairing single-strand breaks in DNA. By blocking this repair pathway, talazoparib induces accumulation of DNA damage in cancer cells, leading to cell death. This mechanism is exceptionally effective in cancer cells that already have deficiencies in other DNA repair pathways, such as those with BRCA mutations.
